All In Biotech

Drug Trial Radar · NCT03747939

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

310

Actual

Start

Dec 31, 2018

Primary completion

Dec 19, 2022

Study completion Jul 5, 2023

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Nov 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.

Conditions

  • Arthritis, Psoriatic

Interventions

  • Apremilast (CC-10004)Drug

    Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive "dummy" titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles.

  • Apremilast (CC-10004) PlaceboOther

    Subjects randomized to placebo will receive "dummy" dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16Time frame: Week 16

Locations

114 sites in 11 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis and Rheumatology Research, PLLC

    Mesa, Arizona

  • Covina Arthritis Clinic

    Covina, California

  • Encino Research Center

    Encino, California

  • Providence Medical Foundation

    Fullerton, California

  • Rheumatology Center of San Diego PC

    San Diego, California

  • East Bay Rheumatology Medical

    San Leandro, California

  • Millennium Clinical Trials

    Thousand Oaks, California

  • Robin K Dore MD Inc

    Tustin, California

  • Inland Rheumatology Clinical Trials Inc

    Upland, California

  • Denver Arthritis Clinic PC

    Denver, Colorado

  • Arthritis and Rheumatic Disease Specialties

    Aventura, Florida

  • Clinical Research of West Florida, Inc

    Clearwater, Florida

  • Center for Rheumatology, Immunology, and Arthritis

    Fort Lauderdale, Florida

  • University of Florida College of Medicine

    Gainesville, Florida

  • Integral Rheumatology and Immunology Specialists

    Plantation, Florida

  • Florida Center For Dermatology

    Saint Augustine, Florida

  • Clinical Research of West Florida Inc

    Tampa, Florida

  • Carol and Frank Morsani Center for Advanced Health Care

    Tampa, Florida

  • Baycare Medical Group Inc

    Tampa, Florida

  • North Georgia Rheumatology Group PC

    Lawrenceville, Georgia

  • RC Rsearch Inc

    Hinsdale, Illinois

  • OrthoIllinois

    Rockford, Illinois

  • Graves Gilbert Clinic

    Bowling Green, Kentucky

  • Clinical Trials Management LLC

    Metairie, Louisiana

  • Klein and Associates MD, PA - Cumberland

    Cumberland, Maryland

  • Klein and Associates MD PA

    Hagerstown, Maryland

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • Advanced Rheumatology PC

    Lansing, Michigan

  • Arthritis and Rheumatology Center of Michigan

    Lansing, Michigan

  • Clinical Research Institute of Michigan

    Saint Clair Shores, Michigan

  • Saint Paul Rheumatology PA

    Eagan, Minnesota

  • Arthritis, Rheumatic, and Back Disease Associates

    Voorhees Township, New Jersey

  • New York University Langone Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Joint and Muscle Research Institute

    Charlotte, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Paramount Medical Research and Consulting LLC

    Middleburg Heights, Ohio

  • Arthritis and Osteoporosis Center of Southwest Ohio

    Middletown, Ohio

  • Health Research of Oklahoma

    Oklahoma City, Oklahoma

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.